ChromoTek introduces novel real-time cell cycle assay for HCA screening

Fluorescent Chromobodies® allow dynamic targeting and tracing of endogenous marker molecules in live cells and represent a versatile tool for cell biologists to monitor multiple parameters defining cellular pathways

Cell Cycle Chromobody® signal during the cell cycle. In G1 the Chromobody® signal is homogeneously distributed throughout the nucleus and cytoplasm. During S phase it accumulates in the nucleus and visualizes the formation of replication foci. In G2 the
(PresseBox) ( Martinsried, )
ChromoTek, a company specializing in bioimaging reagents, has launched the U2OS Cell Cycle Chromobody®, the first real-time HCA screening assay to monitor the complete cell cycle in live cells. The intracellular expression of the fluorescent Cell Cycle Chromobody® enables scientists to simultaneously analyze a set of different cellular parameters: cell size and morphology, nuclear morphology, progression of S phase (early - mid - late stage) and mitosis. This powerful assay enables screening of compounds such as cancer drugs for effects on the cell cycle and toxicity in one experiment. The U2OS Cell Cycle Chromobody® can be applied in early drug development and validation as well as in basic research.

The U2OS Cell Cycle Chromobody® is a cell line stably expressing a small binding protein which targets and traces an endogenous cell cycle marker protein. In contrast to widely used fluorescent fusion proteins, the Cell Cycle Chromobody® provides information about the distribution and dynamics of the native factor. In addition, the Cell Cycle Chromobody® is not cytotoxic and does not affect normal cell function making it an ideal tool for the analysis of molecular processes in the cell in response to external factors such as drug candidates.

With the Cell Cycle Chromobody® ChromoTek introduces a product line for cell scientists who want to analyze cellular processes in real time and to detect dynamic protein-protein interactions in biomedical research and pharmaceutical compound screening. Further Chromobody products addressing other essential cellular pathways will follow soon.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to